Axsome Therapeutics AXSM Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's change in accrued liabilities?
- Axsome Therapeutics (AXSM) reported change in accrued liabilities of $17.23M in Q1 2026.
- How has Axsome Therapeutics's change in accrued liabilities changed year-over-year?
- Axsome Therapeutics's change in accrued liabilities increased by 2006.2% year-over-year, from $818K to $17.23M.
- What is the long-term trend for Axsome Therapeutics's change in accrued liabilities?
- Over 3 years (2022 to 2025), Axsome Therapeutics's change in accrued liabilities has grown at a 24.0% compound annual growth rate (CAGR), from $43.92M to $83.74M.
- What does change in accrued liabilities mean?
- The net change in expenses the company has incurred but not yet paid.
- How do you interpret change in accrued liabilities?
- An increase acts as a source of cash, while a decrease represents a cash outflow.
- How does change in accrued liabilities compare across companies?
- Highly relevant for clinical-stage companies where large research and development accruals are common.